NR-55403来自SARS相关冠状病毒2的刺突糖蛋白受体结合域(RBD),带有C末端组氨酸标签的L452R变体,来自HEK293细胞(蛋白质）的重组
产品图片
货号/SKU
NR-55403
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55403?? Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, L452R Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, L452R Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells|-70°C or colder|ACROBiosystemsAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, L452R Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells, NR-55403.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike (S) glycoprotein receptor binding domain (RBD) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), L452R variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55403 lacks the signal sequence, contains 219 residues of the SARS-CoV-2 S glycoprotein (amino acid residues R319 to K537) and features a C-terminal poly-histidine tag. NR-55403 is from a variant of SARS-CoV-2 which contains the L452R mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55403 has a theoretical molecular weight of 26,600 daltons.
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The L452R mutation has been shown to decrease sensitivity to neutralizing antibodies, increase viral infectivity and enhance viral replication capacity.
The biological activity of NR-55403 was measured by its binding ability in a functional ELISA, in which immobilized NR-55403 at 1 ?g per mL (100 ?L per well) can bind human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257); the linear range is 0.1 to 2 ng per mL.
The biological activity of NR-55403 was also measured by its binding ability using biosensor analysis. Human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257) or Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) can bind NR-55403 with the affinity constants 20.1 nM and 17.4 nM, respectively, using ForteBio Octet Red96e. NR-55403 can bind ACROBiosystems SAD-S35 with an affinity constant of 19.6 nM by Biacore 8K.
Each vial contains approximately 100 ?g of purified recombinant protein lyophilized in phosphate-buffered saline, pH 7.4 and 10% trehalose.
A recombinant form of the spike (S) glycoprotein receptor binding domain (RBD) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), L452R variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55403 lacks the signal sequence, contains 219 residues of the SARS-CoV-2 S glycoprotein (amino acid residues R319 to K537) and features a C-terminal poly-histidine tag. NR-55403 is from a variant of SARS-CoV-2 which contains the L452R mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55403 has a theoretical molecular weight of 26,600 daltons.
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The L452R mutation has been shown to decrease sensitivity to neutralizing antibodies, increase viral infectivity and enhance viral replication capacity.
The biological activity of NR-55403 was measured by its binding ability in a functional ELISA, in which immobilized NR-55403 at 1 ?g per mL (100 ?L per well) can bind human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257); the linear range is 0.1 to 2 ng per mL.
The biological activity of NR-55403 was also measured by its binding ability using biosensor analysis. Human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257) or Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) can bind NR-55403 with the affinity constants 20.1 nM and 17.4 nM, respectively, using ForteBio Octet Red96e. NR-55403 can bind ACROBiosystems SAD-S35 with an affinity constant of 19.6 nM by Biacore 8K.
Each vial contains approximately 100 ?g of purified recombinant protein lyophilized in phosphate-buffered saline, pH 7.4 and 10% trehalose.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2），L452R变体的重组形式，通过人胚胎肾HEK293细胞的瞬时转染，通过亲和力纯化色谱法. NR-55403.
缺乏信号序列，含有219个残基的SARS-COV-2S糖蛋白（氨基酸残基R319至K537），并具有C末端多组合物标签.与SARS-COV-2参考序列（Genpept： QHD43416 ）. NR-55403具有26,600道尔顿的理论分子量.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜.已经显示L452R突变降低对中和抗体的敏感性，增加病毒感染性并提高病毒复制能力.
通过其功能ELISA的结合能力测量NR-55403的生物活性，其中固定的NR-55403在每毫升1μg（每孔100μl）中可以结合人ACE2蛋白（FC标签）（Acrobiosystems AC2-H5257） ;每mL线性范围为0.1至2 ng.
使用生物传感器分析，还通过其结合能力测量NR-55403的生物活性.人ACE2蛋白（FC标签）（Acrobiosystems AC2-H5257）或抗SARS-COV-2 RBD中和抗体，人IgG1（猫.No. SAD-S35）可以将NR-55403与亲和常数20.1nm和17.4nm结合分别使用Fortebio Octet Red96e. NR-55403可以通过Biacore 8K与19.6nm的亲和力常数绑定Acrobiosystems SAD-S35.
每个小瓶含有大约100μg纯化的重组蛋白在磷酸盐缓冲的盐水中冻干，pH7.4和10％海藻糖.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-12-21
2024-09-22
2022-04-01
2024-10-20
2021-12-21
2022-03-31
2024-05-19
2022-04-01
2021-12-13
2024-06-25
2022-04-01